Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of DZD2269 Oral Tablet Following Single and Multiple Ascending Dose Administration to Healthy Adult Participants

NCT04932005 is registered in ClinicalTrials.gov with Dizal Pharmaceuticals as lead sponsor.

NCT NCT04932005
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04932005 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of DZD2269 Oral Tablet Following Single and Multiple Ascending Dose Administration to Healthy Adult Participants
Lead sponsor
Dizal Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
June 29, 2021
Completion date
April 12, 2022
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers